# Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

> **NCT01606878** · PHASE1 · COMPLETED · sponsor: **Children's Oncology Group** · enrollment: 46 (actual)

## Conditions studied

- Childhood Solid Neoplasm
- Recurrent Childhood Anaplastic Large Cell Lymphoma
- Recurrent Neuroblastoma

## Interventions

- **DRUG:** Crizotinib
- **DRUG:** Cyclophosphamide
- **DRUG:** Dexrazoxane Hydrochloride
- **DRUG:** Doxorubicin Hydrochloride
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **OTHER:** Questionnaire Administration
- **DRUG:** Topotecan Hydrochloride
- **DRUG:** Vincristine Sulfate

## Key facts

- **NCT ID:** NCT01606878
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04-29
- **Primary completion:** 2018-12-31
- **Final completion:** 2018-12-31
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2024-01-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01606878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01606878, "Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01606878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*